Radiomic traits extracted from CT imaging of patients with solid tumors (117), H&E images of melanoma and lung cancer (149), and WSIs of patients with breast cancer (152) can determine the response to anti-PD-1/PD-L1 and anti-PD-1 and trastuzumab, respectively. Here, CD274 is linked to breast carcinoma.